Genenta Science is leveraging its Temferon™1 technology platform to treat cancers using a novel immuno-gene therapy approach
1: Temferon™ is an Investigational Advanced Therapy Medicinal Product (ATMP) consisting of autologous CD34+-TEM enriched Hematopoietic Stem and Progenitor Cells (HSPC) transduced with a Lentiviral Vector (LV) encoding the human interferon-α2 (IFN-α2) gene. The expression of the gene within the tumor microenvironment is regulated by TEM-specific promoter and microRNA-126 (miR-126).
2: Genenta Science plans to enroll the first patient in 1/2Q19 (TEM-MM-101 study)
3: Genenta Science plans to enroll the first patient in 1Q19 (TEM-GBM_001 study)